• Since late 2002, we have delivered 13 important new products to patients in need, including three in 2011 alone.
• Since 2007, we have executed 18 transactions under our business development strategy, called String of Pearls – a series of select acquisitions and alliances with biotech partners through a series of highly strategic transactions in targeted disease areas.
• Biologics account for about one-third of our compounds in development.
• We invested $3.8 billion in research & development in 2011.

• ABILIFY® (aripiprazole), November 2002, new molecular entity
• REYATAZ® (atazanavir sulfate), June 2003, new molecular entity
• ERBITUX® (cetuximab), February 2004, new molecular entity
• BARACLUDE® (entecavir), March 2005, new molecular entity
• ORENCIA® (abatacept), December 2005, new molecular entity
• SPRYCEL® (dasatinib), June 2006, new molecular entity
• ATRIPLA® (efavirenz / emtricitabine /tenofovir disoproxil fumarate), July 2006
• IXEMPRA™ (ixabepilone), October 2007, new molecular entity
• ONGLYZA™ (saxagliptin), July 2009, new molecular entity
• KOMBIGYLZE™ XR (saxagliptin and metformin HCI extended release), November 2010
• YERVOY™ (ipilimumab), new molecular entity, March 2011
• NULOJIX® (belatacept), new molecular entity, June 2011

May 2012
Bristol-Myers Squibb Company and Tsinghua University of Beijing, China,announced the formation of a multi-year strategic partnership. Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University’s School of Life Sciences to identify and validate novel targets in oncology and immunoscience.

March 2012
Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer’s Disease

February 2012
Bristol-Myers Squibb and Duke Translational Medicine Institute Form Strategic Relationship to Broaden Interactions

Bristol-Myers Squibb Completes Acquisition of Inhibitex, Inc.

December 2011
Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer’s Disease

Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound

Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C

November 2011
ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership to License and Develop Investigational Oncology Compound

October 2011
Company Receives Skin Sense Award by the Skin Cancer Foundation for YERVOY™ (ipilimumab)

September 2011
Bristol-Myers Squibb Scientist John E. Macor Recognized as 2011 Fellow of the American Chemical Society for Significant Contribution to Medicinal Chemistry

Bristol-Myers Squibb Scientist Tanya Fischer Receives Presidential Early Career Award for Scientists and Engineers

Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure

Bristol-Myers Squibb and Saladax Biomedical Expand Collaboration for Diagnostic Assays for Alzheimer’s Disease

Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)

Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals

July 2011
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology Biologic

June 2011
Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY™ (ipilimumab) and Vemurafenib

March 2011
Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility

January 2011
Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement for Proof of Concept Combination Study in Patients Chronically Infected with Hepatitis C

R&D Directions Names Bristol-Myers Squibb’s Pipeline Most Innovative

December 2010
Cleveland Clinic Names Ipilimumab a Top Innovation

Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement for Investigational HIV Compound

November 2010
Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Early-Stage Oncology Compound

October 2010
Ipilimumab Team Receives the 2010 Vision of Hope Award from the Melanoma Research Foundation

Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc.

June 2010
Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL to Support Greater Efficiencies in Clinical Development

March 2010
Bristol-Myers Squibb and Allergan, Inc. Announce Global Agreement for Development and Commercialization of an Oral Medication for Treatment of Neuropathic Pain

Please click on the product links to see the Full Prescribing Information including Boxed WARNINGS for ABILIFY®, ATRIPLA®, BARACLUDE®, and NULOJIX®, Boxed WARNING for YERVOY™ regarding immune-mediated adverse reactions, and Boxed WARNINGS for ERBITUX® regarding infusion reactions and cardiopulmonary arrest.

Click here for trademark information on Bristol-Myers Squibb products.

May, 2012